LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

AbbVie Inc

Cerrado

SectorSanidad

186.94 0.72

Resumen

Variación precio

24h

Actual

Mínimo

185.13

Máximo

188.92

Métricas clave

By Trading Economics

Ingresos

1.3B

1.3B

Ventas

-1.8B

13B

P/B

Media del Sector

79.528

50.291

BPA

2.46

Rentabilidad por dividendo

3.54

Margen de beneficios

9.66

Empleados

55,000

EBITDA

3.2B

3.7B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+14.79% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.54%

2.40%

Próximas Ganancias

24 jul 2025

Fecha Próximo Dividendo

15 ago 2025

Próxima Fecha de Ex Dividendo

15 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-16B

327B

Apertura anterior

186.22

Cierre anterior

186.94

Noticias sobre sentimiento de mercado

By Acuity

24%

76%

53 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

AbbVie Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 abr 2025, 13:57 UTC

Ganancias

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 abr 2025, 12:52 UTC

Ganancias

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

9 abr 2025, 18:18 UTC

Principales Movimientos del Mercado

Pharma Shares Reverse Losses After Tariff Pause

9 abr 2025, 09:39 UTC

Principales Movimientos del Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

27 feb 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12 feb 2025, 13:41 UTC

Principales Movimientos del Mercado

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

7 may 2025, 09:30 UTC

Principales Noticias

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 abr 2025, 12:44 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 abr 2025, 09:33 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 abr 2025, 16:03 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 abr 2025, 14:00 UTC

Principales Noticias
Ganancias

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 abr 2025, 12:24 UTC

Principales Noticias
Ganancias

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 abr 2025, 12:03 UTC

Principales Noticias
Ganancias

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q International HUMIRA Rev $377M >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Global Skyrizi Rev $3.43B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Net $1.29B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Global IMBRUVICA Rev $738M >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q EPS 72c >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Adj EPS $2.46 >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie 1Q Rev $13.34B >ABBV

25 abr 2025, 11:43 UTC

Ganancias

AbbVie Sees FY Adj EPS $12.09-Adj EPS $12.29 >ABBV

14 mar 2025, 09:30 UTC

Principales Noticias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3 mar 2025, 15:04 UTC

Adquisiciones, fusiones, absorciones

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 feb 2025, 13:25 UTC

Principales Noticias
Ganancias

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 feb 2025, 12:00 UTC

Ganancias

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5 feb 2025, 12:00 UTC

Principales Noticias

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31 ene 2025, 15:50 UTC

Principales Noticias
Ganancias

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

Comparación entre iguales

Cambio de precio

AbbVie Inc previsión

Precio Objetivo

By TipRanks

14.79% repunte

Estimación a 12 Meses

Media 212.8 USD  14.79%

Máximo 250 USD

Mínimo 170 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbbVie Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

17 ratings

11

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

180.37 / 195.54Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

53 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.